261 related articles for article (PubMed ID: 16326085)
1. Use of kappa-carrageenan as alternative pelletisation aid to microcrystalline cellulose in extrusion/spheronisation. I. Influence of type and fraction of filler.
Thommes M; Kleinebudde P
Eur J Pharm Biopharm; 2006 May; 63(1):59-67. PubMed ID: 16326085
[TBL] [Abstract][Full Text] [Related]
2. Use of kappa-carrageenan as alternative pelletisation aid to microcrystalline cellulose in extrusion/spheronisation. II. Influence of drug and filler type.
Thommes M; Kleinebudde P
Eur J Pharm Biopharm; 2006 May; 63(1):68-75. PubMed ID: 16325384
[TBL] [Abstract][Full Text] [Related]
3. Effect of drying on extruded pellets based on kappa-carrageenan.
Thommes M; Blaschek W; Kleinebudde P
Eur J Pharm Sci; 2007 Jun; 31(2):112-8. PubMed ID: 17448646
[TBL] [Abstract][Full Text] [Related]
4. Influence of MCC II fraction and storage conditions on pellet properties.
Krueger C; Thommes M; Kleinebudde P
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1039-45. PubMed ID: 23872176
[TBL] [Abstract][Full Text] [Related]
5. Quantification of mass transfer during spheronisation.
Koester M; Thommes M
AAPS PharmSciTech; 2012 Jun; 13(2):493-7. PubMed ID: 22415640
[TBL] [Abstract][Full Text] [Related]
6. Production of pellets via extrusion-spheronisation without the incorporation of microcrystalline cellulose: a critical review.
Dukić-Ott A; Thommes M; Remon JP; Kleinebudde P; Vervaet C
Eur J Pharm Biopharm; 2009 Jan; 71(1):38-46. PubMed ID: 18771727
[TBL] [Abstract][Full Text] [Related]
7. Use of crospovidone as pelletization aid as alternative to microcrystalline cellulose: effects on pellet properties.
Verheyen P; Steffens KJ; Kleinebudde P
Drug Dev Ind Pharm; 2009 Nov; 35(11):1325-32. PubMed ID: 19832632
[TBL] [Abstract][Full Text] [Related]
8. Preliminary assessment of carrageenan as excipient for extrusion/spheronisation.
Bornhöft M; Thommes M; Kleinebudde P
Eur J Pharm Biopharm; 2005 Jan; 59(1):127-31. PubMed ID: 15567309
[TBL] [Abstract][Full Text] [Related]
9. Suitability of κ-carrageenan pellets for the formulation of multiparticulate tablets with modified release.
Ghanam D; Kleinebudde P
Int J Pharm; 2011 May; 409(1-2):9-18. PubMed ID: 21335073
[TBL] [Abstract][Full Text] [Related]
10. Immediate release pellets with lipid binders obtained by solvent-free cold extrusion.
Krause J; Thommes M; Breitkreutz J
Eur J Pharm Biopharm; 2009 Jan; 71(1):138-44. PubMed ID: 18805483
[TBL] [Abstract][Full Text] [Related]
11. Compression behaviour of kappa-carrageenan pellets.
Ghanam D; Hassan I; Kleinebudde P
Int J Pharm; 2010 May; 390(2):117-27. PubMed ID: 20100553
[TBL] [Abstract][Full Text] [Related]
12. The behavior of different carrageenans in pelletization by extrusion/spheronization.
Thommes M; Kleinebudde P
Pharm Dev Technol; 2008; 13(1):27-35. PubMed ID: 18300097
[TBL] [Abstract][Full Text] [Related]
13. Drug release from MCC- and carrageenan-based pellets: experiment and theory.
Kranz H; Jürgens K; Pinier M; Siepmann J
Eur J Pharm Biopharm; 2009 Oct; 73(2):302-9. PubMed ID: 19465119
[TBL] [Abstract][Full Text] [Related]
14. In-vitro and in-vivo evaluation of enteric-coated starch-based pellets prepared via extrusion/spheronisation.
Dukić-Ott A; De Beer T; Remon JP; Baeyens W; Foreman P; Vervaet C
Eur J Pharm Biopharm; 2008 Sep; 70(1):302-12. PubMed ID: 18579353
[TBL] [Abstract][Full Text] [Related]
15. Properties of pellets manufactured by wet extrusion/spheronization process using kappa-carrageenan: effect of process parameters.
Thommes M; Kleinebudde P
AAPS PharmSciTech; 2007 Nov; 8(4):E95. PubMed ID: 18181555
[TBL] [Abstract][Full Text] [Related]
16. Multiple batch manufacturing of theophylline pellets using the wet-extrusion/spheronization process with κ-carrageenan as pelletisation aid.
Krueger C; Thommes M
Pharm Dev Technol; 2013 Feb; 18(1):225-35. PubMed ID: 22780876
[TBL] [Abstract][Full Text] [Related]
17. Use of к-carrageenan, chitosan and Carbopol 974P in extruded and spheronized pellets that are devoid of MCC.
Valle BL; Omwancha WS; Neau SH; Wigent RJ
Drug Dev Ind Pharm; 2016 Nov; 42(11):1903-16. PubMed ID: 27100683
[TBL] [Abstract][Full Text] [Related]
18. Systematic evaluations regarding interparticular mass transfer in spheronization.
Koester M; Willemsen E; Krueger C; Thommes M
Int J Pharm; 2012 Jul; 431(1-2):84-9. PubMed ID: 22546294
[TBL] [Abstract][Full Text] [Related]
19. Development of starch-based pellets via extrusion/spheronisation.
Dukić A; Mens R; Adriaensens P; Foreman P; Gelan J; Remon JP; Vervaet C
Eur J Pharm Biopharm; 2007 Apr; 66(1):83-94. PubMed ID: 17045467
[TBL] [Abstract][Full Text] [Related]
20. Improved bioavailability of darunavir by use of kappa-carrageenan versus microcrystalline cellulose as pelletisation aid.
Thommes M; Baert L; van 't Klooster G; Geldof M; Schueller L; Rosier J; Kleinebudde P
Eur J Pharm Biopharm; 2009 Aug; 72(3):614-20. PubMed ID: 19303929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
